# Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

> Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways - Healthcare Publication

- Base URL: https://www.targetedonc.com
- Generated: 2026-10-21T00:19:09.122Z
- Content updates: multiple times daily

## Content Access for AI Agents

This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML.

**Supported content types:**
- `text/markdown` — Clean Markdown with YAML frontmatter
- `text/plain` — Plain text (same as Markdown)
- `text/html` — Default HTML response

**Example request:**
```
curl -H "Accept: text/markdown" https://www.targetedonc.com/view/article-slug
```

**YAML frontmatter schema** (returned with every Markdown response):

| Field | Type | Description |
|-------|------|-------------|
| `title` | string | Article headline |
| `description` | string | Summary/excerpt (max 300 chars) |
| `url` | string | Canonical article URL |
| `canonical_url` | string | Canonical URL if different from `url` |
| `published` | ISO 8601 | Original publication date |
| `modified` | ISO 8601 | Last modification date |
| `authors` | string[] | Author display names |
| `content_type` | string | Content category (e.g., "News", "Clinical") |
| `categories` | string[] | Taxonomy categories |
| `tags` | string[] | SEO tags |
| `image` | string | Featured image URL |
| `publisher` | string | Publication/site name |

**Discovery headers** (included on all responses):
- `Link: <https://www.targetedonc.com/llms.txt>; rel="llms"` — RFC 8288 link to this file
- `X-Llms-Txt: https://www.targetedonc.com/llms.txt` — Explicit discovery header

## Usage Policy

- Robots policy: [https://www.targetedonc.com/robots.txt](https://www.targetedonc.com/robots.txt)
- Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329)
- Rate guidance: prefer RSS and sitemap feeds over crawling individual pages
- Attribution: All content © MJH Life Sciences. Include source URLs when citing.

## Content Categories

- [10th Anniversary](https://www.targetedonc.com/10th-anniversary)
- [CCC Elevate](https://www.targetedonc.com/ccc-elevate)
- [Case Based Peer Perspectives](https://www.targetedonc.com/case-based-peer-perspectives)
- [Case-Based Roundtable™](https://www.targetedonc.com/case-based-roundtable-series)
- [Clinical](https://www.targetedonc.com/clinical)
- [Clinical Trials](https://www.targetedonc.com/clinical-trials)
- [Conference News](https://www.targetedonc.com/conference)
- [Expert Perspective Tumor Board](https://www.targetedonc.com/expert-perspective-tumor-board)
- [Interviews](https://www.targetedonc.com/interviews)
- [Investigator Perspectives](https://www.targetedonc.com/investigator-perspectives)
- [News](https://www.targetedonc.com/news)
- [Oncology Icons](https://www.targetedonc.com/oncology-icons)
- [Podcasts](https://www.targetedonc.com/podcasts)
- [Precision Medicine](https://www.targetedonc.com/precision-medicine)
- [Press Releases](https://www.targetedonc.com/press-releases)
- [Publications](https://www.targetedonc.com/publications)
- [Sponsored Content](https://www.targetedonc.com/sponsored)
- [Video Programs](https://www.targetedonc.com/video-programs)

## Featured Content

- [Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma](https://www.targetedonc.com/view/oncologists-debate-role-of-on-body-injector-for-transplant-ineligible-myeloma): During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient...
- [MC001 Receives FDA Fast Track Designation in Pancreatic Cancer](https://www.targetedonc.com/view/mc001-receives-fda-fast-track-designation-in-pancreatic-cancer): The investigational chemoimmunotherapy antibody-drug conjugate demonstrated enhanced tumor inhibition in preclinical models.
- [Casdatifan Shows Activity Across Treatment Lines in ccRCC](https://www.targetedonc.com/view/casdatifan-ab521-multiple-treatment-lines-ccrcc-arc-20): Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone and in key first-line com...
- [Rural-Urban Breast Cancer Mortality Gap Projected to Widen in Next Decade](https://www.targetedonc.com/view/rural-urban-breast-cancer-mortality-disparity-2035): Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by...
- [Vilamakitug Meets Phase 2 Efficacy Criterion in Refractory Metastatic Colorectal Cancer](https://www.targetedonc.com/view/vilamakitug-meets-primary-efficacy-criterion-refractory-mcrc): The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting...
- [Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC](https://www.targetedonc.com/view/bazhenova-taletrectinib-expanded-approval-ros1-nsclc): Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
- [FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC](https://www.targetedonc.com/view/fda-accepts-nda-for-ugn-103-in-recurrent-lg-ir-nmibc): UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA rev...
- [Upfront Surgery Vs Total Neoadjuvant Therapy in Rectal Cancer](https://www.targetedonc.com/view/upfront-surgery-vs-total-neoadjuvant-therapy-in-rectal-cancer): Ryan Moore, MD, discusses the choice between surgery and total neoadjuvant therapy (TNT) for rectal cancer and when watch-and-wait is feasible post-TN...
- [Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer](https://www.targetedonc.com/view/dostarlimab-fda-approval-locally-advanced-rectal-cancer): FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radia...
- [Neoadjuvant Radiation Before IVC Thrombectomy Meets RFS Goal in RCC](https://www.targetedonc.com/view/neoadjuvant-radiation-before-ivc-thrombectomy-meets-rfs-goal-in-rcc): SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could be used to reduce invasiv...

## Feeds and Indexes

- [RSS Feed](https://www.targetedonc.com/rss.xml): Latest articles in XML syndication format
- [Sitemap](https://www.targetedonc.com/sitemap.xml): Complete URL index for all published pages
- [News Sitemap](https://www.targetedonc.com/sitemap-news.xml): Recent articles optimized for news indexing
- [Authors Directory](https://www.targetedonc.com/authors): Browse all contributors and their published work